BRAFTOVI + ERBITUX
The combination of encorafenib (Pfizer) and cetuximab (Eli Lilly) is used in biomarker-selected colorectal cancer settings involving BRAF alterations.
Where this therapy is approved with a companion diagnostic
Each row represents a defined combination of indication, biomarker criteria, and BRAFTOVI + ERBITUX. Select a testing pathway to see the eligible companion diagnostic tests.
Approvals where BRAFTOVI + ERBITUX is tied to a specific indication and biomarker definition.
| Indication | Biomarker criteria | Notes | |
|---|---|---|---|
Metastatic Colorectal Cancer (mCRC) Solid Tumor · Colorectal | BRAF
| View testing pathway → | |
Colorectal Cancer (CRC) Solid Tumor · Colorectal | BRAF
| View testing pathway → |
Approvals defined at the solid tumor level where biomarker criteria determine eligibility for BRAFTOVI + ERBITUX.
No tumor-agnostic companion diagnostic approvals are currently mapped for this therapy.
Tests used in these approvals
These assays are identified in FDA labeling or sponsor materials as companion diagnostics or acceptable tests when considering BRAFTOVI + ERBITUX for eligible patients.